Senti Bio Raises $105m Series B Round For CAR-NKs, Led By Leaps For Bayer
Company Anticipates IND Filing In 2022-2023
The investment is the latest in Bayer’s series of moves into cell and gene therapy, amid growing industry interest in CAR-NKs.
You may also be interested in...
After accumulating technologies to develop off-the-shelf, allogeneic NK cell therapies over the past decade, Korea's GC LabCell is now tapping into the global market as US partner Artiva begins clinical trials of its lead asset.
Another victim of the COVID-pandemic, Celgene's $9-per-share contingent value right tied to BMS obtaining approval of three drugs goes unrealized due to FDA travel restrictions slowing down site inspections. Clene goes public, United Therapeutics buys PRV from Y-mAbs.
The last six weeks have seen the acquisition of AskBio, the launch of a dedicated cell and gene therapy unit and a CAR-T pact with Atara. Bayer is taking the space very seriously.